医療従事者の為の最新医療ニュースや様々な情報・ツールを提供する医療総合サイト

ResMed to Report Third Quarter Fiscal 2019 Earnings on May 2, 2019

2019年04月12日 AM05:05
このエントリーをはてなブックマークに追加


 

SAN DIEGO

ResMed (NYSE: RMD, ASX: RMD) today announced it plans to release financial and operational results for the third quarter of fiscal year 2019 on Thursday, May 2, 2019, after the New York Stock Exchange closes. Following the release, ResMed management will host a webcast to discuss these results. Other forward-looking and material information may also be discussed during this call.

Earnings webcast details:

       

  Location:      

http://investor.resmed.com

Date: Thursday, May 2, 2019

Time: 1:30 p.m. PT / 4:30 p.m. ET

International: London, Thursday, May 2, 9:30 p.m.
Sydney, Friday, May 3, 6:30 a.m.
 

Please note that ResMed does not use outside phone lines to access the earnings call.

A replay of the earnings webcast will be accessible on ResMed’s website and available approximately two hours after the webcast. In addition, a phone replay will be available approximately two hours after the webcast and will be accessible from May 2 until May 16 at:

       

  U.S.:       +1 800.585.8367

International: +1 416.621.4642

Passcode: 3977963
 

About ResMed

At ResMed (NYSE: RMD, ASX: RMD) we pioneer innovative solutions that treat and keep people out of the hospital, empowering them to live healthier, higher-quality lives. Our cloud-connected medical devices transform care for people with sleep apnea, COPD and other chronic diseases. Our comprehensive out-of-hospital software platforms support the professionals and caregivers who help people stay healthy in the home or care setting of their choice. By enabling better care, we improve quality of life, reduce the impact of chronic disease and lower costs for consumers and healthcare systems in more than 120 countries. To learn more, visit ResMed.com and follow @ResMed.

View source version on businesswire.com: https://www.businesswire.com/news/home/20190411005679/en/

CONTACT

For media:
Jayme Rubenstein
+1 858.836.6798
news@resmed.com

For investors:
Amy Wakeham
+1 858.836.5000
investorrelations@resmed.com

Related Posts Plugin for WordPress, Blogger...

同じカテゴリーの記事 

  • アスターDMヘルスケア、25万米ドル相当の世界看護賞を発表
  • Prestige BioPharma Enters MOU with Busan City for Establishment of its R&D Centre in Busan, South Korea
  • Celltrion Confirms Neutralising Potency Against Emerging SARS-CoV-2 Variants With Anti-COVID-19 Monoclonal Antibody Treatment regdanvimab (CT-P59)
  • InnoCare Announces Approval of Clinical Trial of TYK2 Inhibitor ICP-332 in China
  • 患者安全运动基金会公布参加首届医疗安全研究员项目五人名单